INVESTOR RELATIONS

Investor relations

NEWS

Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2025. In accordance with the decision at the Annual...
Lipum AB (publ), a Swedish biopharmaceutical company focusing on innovative treatments for chronic inflammatory diseases, presented positive findings from...
Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available...
Lipum AB (publ) announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in...
Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO). Peter Hovstadius is a specialist in clinical pharmacology with a PhD...
Lipum AB (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced...
Lipum AB (publ) has published the interim report Q2 for the period January-June 2024. Below is a summary, a complete report (only in Swedish) is available...
Lipum AB (publ) received in August 2018 a M€ 2.2 / MSEK 23 grant from the European Commission innovation program Horizon 2020. The successful project...
Lipum AB (publ) announces that the multiple dose part of the phase I clinical study is completed. Eight healthy subjects have received four doses 28 days...
Lipum AB (publ) has published the interim report Q1 for the period January-March 2024. Below is a summary, a complete report (only in Swedish) is available...

INVESTOR RELATIONS

Investor relations